William W Chance1, David C Rice2, Pamela K Allen1, Anne S Tsao3, Hiral P Fontanilla4, Zhongxing Liao1, Joe Y Chang1, Chad Tang1, Hubert Y Pan1, James W Welsh1, Reza J Mehran2, Daniel R Gomez5. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Princeton Radiation Oncology, Monroe Township, New Jersey. 5. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: dgomez@mdanderson.org.
Abstract
PURPOSE: To investigate safety, efficacy, and recurrence after hemithoracic intensity modulated radiation therapy after pleurectomy/decortication (PD-IMRT) and after extrapleural pneumonectomy (EPP-IMRT). METHODS AND MATERIALS: In 2009-2013, 24 patients with mesothelioma underwent PD-IMRT to the involved hemithorax to a dose of 45 Gy, with an optional integrated boost; 22 also received chemotherapy. Toxicity was scored with the Common Terminology Criteria for Adverse Events v4.0. Pulmonary function was compared at baseline, after surgery, and after IMRT. Kaplan-Meier analysis was used to calculate overall survival (OS), progression-free survival (PFS), time to locoregional failure, and time to distant metastasis. Failures were in-field, marginal, or out of field. Outcomes were compared with those of 24 patients, matched for age, nodal status, performance status, and chemotherapy, who had received EPP-IMRT. RESULTS: Median follow-up time was 12.2 months. Grade 3 toxicity rates were 8% skin and 8% pulmonary. Pulmonary function declined from baseline to after surgery (by 21% for forced vital capacity, 16% for forced expiratory volume in 1 second, and 19% for lung diffusion of carbon monoxide [P for all = .01]) and declined still further after IMRT (by 31% for forced vital capacity [P=.02], 25% for forced expiratory volume in 1 second [P=.01], and 30% for lung diffusion of carbon monoxide [P=.01]). The OS and PFS rates were 76% and 67%, respectively, at 1 year and 56% and 34% at 2 years. Median OS (28.4 vs 14.2 months, P=.04) and median PFS (16.4 vs 8.2 months, P=.01) favored PD-IMRT versus EPP-IMRT. No differences were found in grade 4-5 toxicity (0 of 24 vs 3 of 24, P=.23), median time to locoregional failure (18.7 months vs not reached, P not calculable), or median time to distant metastasis (18.8 vs 11.8 months, P=.12). CONCLUSIONS: Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication produced little high-grade toxicity but led to progressive declines in pulmonary function; OS and PFS were better in PD-IMRT compared with EPP-IMRT.
PURPOSE: To investigate safety, efficacy, and recurrence after hemithoracic intensity modulated radiation therapy after pleurectomy/decortication (PD-IMRT) and after extrapleural pneumonectomy (EPP-IMRT). METHODS AND MATERIALS: In 2009-2013, 24 patients with mesothelioma underwent PD-IMRT to the involved hemithorax to a dose of 45 Gy, with an optional integrated boost; 22 also received chemotherapy. Toxicity was scored with the Common Terminology Criteria for Adverse Events v4.0. Pulmonary function was compared at baseline, after surgery, and after IMRT. Kaplan-Meier analysis was used to calculate overall survival (OS), progression-free survival (PFS), time to locoregional failure, and time to distant metastasis. Failures were in-field, marginal, or out of field. Outcomes were compared with those of 24 patients, matched for age, nodal status, performance status, and chemotherapy, who had received EPP-IMRT. RESULTS: Median follow-up time was 12.2 months. Grade 3 toxicity rates were 8% skin and 8% pulmonary. Pulmonary function declined from baseline to after surgery (by 21% for forced vital capacity, 16% for forced expiratory volume in 1 second, and 19% for lung diffusion of carbon monoxide [P for all = .01]) and declined still further after IMRT (by 31% for forced vital capacity [P=.02], 25% for forced expiratory volume in 1 second [P=.01], and 30% for lung diffusion of carbon monoxide [P=.01]). The OS and PFS rates were 76% and 67%, respectively, at 1 year and 56% and 34% at 2 years. Median OS (28.4 vs 14.2 months, P=.04) and median PFS (16.4 vs 8.2 months, P=.01) favored PD-IMRT versus EPP-IMRT. No differences were found in grade 4-5 toxicity (0 of 24 vs 3 of 24, P=.23), median time to locoregional failure (18.7 months vs not reached, P not calculable), or median time to distant metastasis (18.8 vs 11.8 months, P=.12). CONCLUSIONS: Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication produced little high-grade toxicity but led to progressive declines in pulmonary function; OS and PFS were better in PD-IMRT compared with EPP-IMRT.
Authors: A Botticella; G Defraene; K Nackaerts; C Deroose; J Coolen; P Nafteux; B Vanstraelen; S Joosten; L A W Michiels; S Peeters; D De Ruysscher Journal: Strahlenther Onkol Date: 2017-02-14 Impact factor: 3.621
Authors: Christina Leitzen; Timo Wilhelm-Buchstab; Sabina Stumpf; Martina Heimann; David Koch; Christopher Schmeel; Birgit Simon; Susanne Vornholt; Stephan Garbe; Fred Röhner; Felix Schoroth; Hans Heinz Schild; Heinrich Schüller; Thomas Müdder Journal: Strahlenther Onkol Date: 2019-03-26 Impact factor: 3.621
Authors: David B Nelson; David C Rice; Kyle G Mitchell; Anne S Tsao; Ara A Vaporciyan; Mara B Antonoff; Wayne L Hofstetter; Garrett L Walsh; Stephen G Swisher; Jack A Roth; Daniel R Gomez; Reza J Mehran; Boris Sepesi Journal: J Thorac Dis Date: 2019-04 Impact factor: 2.895
Authors: Christian Thieke; Nils H Nicolay; Florian Sterzing; Hans Hoffmann; Falk Roeder; Seyer Safi; Juergen Debus; Peter E Huber Journal: Radiat Oncol Date: 2015-12-30 Impact factor: 3.481
Authors: Christina Schröder; Isabelle Opitz; Matthias Guckenberger; Rolf Stahel; Walter Weder; Robert Förster; Nicolaus Andratschke; Olivia Lauk Journal: Front Oncol Date: 2019-09-26 Impact factor: 6.244
Authors: Oscar Arrieta; Francisco Lozano-Ruiz; Monika Blake-Cerda; Rodrigo Catalán; Luis Lara-Mejía; Miguel Ángel Salinas; Federico Maldonado-Magos; José F Corona-Cruz Journal: Thorac Cancer Date: 2020-10-08 Impact factor: 3.500